Category: Citius

  • Dr. Reddy’s Collaborates with Citius to Sell Rights of its Anti-Cancer Agent (E7777)

    Shots: Dr. Reddy’s to receive $40M up front upon the closing of the transaction, followed by ~$40M milestones on E7777’s approval in CTCL and ~$70M for additional indication approvals. Additionally, Dr. Reddy’s will receive commercial milestones and royalties Citius to get all the rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related […]